Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 95 citing articles:

The Tabula Sapiens: A multiple-organ, single-cell transcriptomic atlas of humans
The Tabula Sapiens Consortium, Robert C. Jones, Jim Karkanias, et al.
Science (2022) Vol. 376, Iss. 6594
Open Access | Times Cited: 619
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Hye Won Lee, Woosung Chung, Hae‐Ock Lee, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 152
The dynamic roles of the bladder tumour microenvironment
Yu‐Cheng Lee, Hung‐Ming Lam, Charles J. Rosser, et al.
Nature Reviews Urology (2022) Vol. 19, Iss. 9, pp. 515-533
Open Access | Times Cited: 48
Preclinical models of bladder cancer: BBN and beyond
David Matye, Juliann Leak, Benjamin L. Woolbright, et al.
Nature Reviews Urology (2024) Vol. 21, Iss. 12, pp. 723-734
Closed Access | Times Cited: 7
Regulation of efferocytosis as a novel cancer therapy
Yunxiang Zhou, Yihan Yao, Yongchuan Deng, et al.
Cell Communication and Signaling (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 60
The Tabula Sapiens: a multiple organ single cell transcriptomic atlas of humans
Stephen R. Quake
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 54
Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects
Soo Young Cho, Heeyoun Hwang, Yun‐Hee Kim, et al.
Gastroenterology (2023) Vol. 164, Iss. 7, pp. 1293-1309
Closed Access | Times Cited: 19
Epigenetic and Immunological Features of Bladder Cancer
I. R. Gilyazova, Kadriia Enikeeva, Guzel Rafikova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9854-9854
Open Access | Times Cited: 16
Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity
Aline Atallah, Arielle Grossman, Richard W. Nauman, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 2, pp. 352-364
Open Access | Times Cited: 6
Mechanism of action of nadofaragene firadenovec-vncg
Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Single-cell RNA-binding protein pattern-mediated molecular subtypes depict the hallmarks of the tumor microenvironment in bladder urothelial carcinoma
Jun Zhang, Jiejie He, Wen Chen, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 4, pp. 657-669
Open Access | Times Cited: 5
Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies
Inmaculada Ruiz-Lorente, Lourdes Gimeno, Alicia López-Abad, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 156-156
Open Access
Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
Beatriz Ramos‐Solano, Dakota Rogers
annals of urologic oncology (2025)
Open Access
Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture
Haoyang Mi, Trinity J. Bivalacqua, Max Kates, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 9, pp. 100382-100382
Open Access | Times Cited: 32
Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications
Emanuela Germanà, Ludovica Pepe, Cristina Pizzimenti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6750-6750
Open Access | Times Cited: 4
Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy
Mayra Fernanda Martínez-López, Cátia Rebelo de Almeida, Márcia Fontes, et al.
Disease Models & Mechanisms (2024) Vol. 17, Iss. 8
Open Access | Times Cited: 4
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy
Moshe Chaim Ornstein, C. Marcela Díaz‐Montero, Patricia Rayman, et al.
Urologic Oncology Seminars and Original Investigations (2018) Vol. 36, Iss. 9, pp. 405-412
Closed Access | Times Cited: 42
Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer
Faping Li, Haolin Teng, Mingdi Liu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 38
Immune contexture analysis in immuno‐oncology: applications and challenges of multiplex fluorescent immunohistochemistry
Reshma Shakya, Tam H. Nguyen, Nigel J. Waterhouse, et al.
Clinical & Translational Immunology (2020) Vol. 9, Iss. 10
Open Access | Times Cited: 34
Significance of tumor-associated neutrophils, lymphocytes, and neutrophil-to-lymphocyte ratio in non-invasive and invasive bladder urothelial carcinoma
Wael Abdo Hassan, Ahmed Kamal ElBanna, Noha Noufal, et al.
Journal of Pathology and Translational Medicine (2023) Vol. 57, Iss. 2, pp. 88-94
Open Access | Times Cited: 10
Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel
Mohamad Abou Chakra, Riitta Lassila, Nancy El Beayni, et al.
BJU International (2024) Vol. 135, Iss. 1, pp. 125-132
Closed Access | Times Cited: 3
Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer
Yuxuan Song, Donghui Jin, Jingyi Chen, et al.
Aging (2020) Vol. 12, Iss. 12, pp. 12051-12073
Open Access | Times Cited: 30
Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette–Guérin
Jung Hoon Kim, Seungjin Lee, Su Jeong Kang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8887-8887
Open Access | Times Cited: 24
PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification
Sara Feola, Markus Haapala, Karita Peltonen, et al.
ACS Nano (2021) Vol. 15, Iss. 10, pp. 15992-16010
Open Access | Times Cited: 23
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer
Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang’, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top